TD Asset Management Inc Buys 9,400 Shares of Tarsus Pharmaceuticals, Inc. $TARS

TD Asset Management Inc boosted its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 21.7% in the third quarter, Holdings Channel reports. The firm owned 52,692 shares of the company’s stock after acquiring an additional 9,400 shares during the period. TD Asset Management Inc’s holdings in Tarsus Pharmaceuticals were worth $3,131,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Federated Hermes Inc. raised its position in shares of Tarsus Pharmaceuticals by 0.6% in the second quarter. Federated Hermes Inc. now owns 55,021 shares of the company’s stock valued at $2,229,000 after purchasing an additional 339 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Tarsus Pharmaceuticals by 6.2% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,626 shares of the company’s stock valued at $349,000 after buying an additional 505 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 9.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 8,438 shares of the company’s stock valued at $342,000 after buying an additional 740 shares during the last quarter. Franklin Resources Inc. raised its holdings in Tarsus Pharmaceuticals by 3.6% in the 2nd quarter. Franklin Resources Inc. now owns 21,402 shares of the company’s stock worth $867,000 after acquiring an additional 750 shares during the period. Finally, Profund Advisors LLC lifted its position in Tarsus Pharmaceuticals by 12.7% during the 2nd quarter. Profund Advisors LLC now owns 9,469 shares of the company’s stock worth $384,000 after acquiring an additional 1,064 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 7,397 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total value of $592,499.70. Following the completion of the transaction, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at $70,792,837.41. The trade was a 0.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 8.97% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Guggenheim upped their price target on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $87.00.

Tarsus Pharmaceuticals Trading Down 0.5%

Tarsus Pharmaceuticals stock opened at $76.20 on Thursday. The business has a 50 day moving average price of $71.65 and a two-hundred day moving average price of $69.21. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a 12 month low of $38.51 and a 12 month high of $85.25. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of -47.04 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million for the quarter, compared to analyst estimates of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. As a group, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.